TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis [3] - BRIUMVI has also been approved by regulatory agencies in Europe, the UK, Switzerland, and Australia for treating adult patients with active relapsing multiple sclerosis [3] Upcoming Events - Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will participate in the Cantor Global Healthcare Conference scheduled for September 3-5, 2025 [1] - A fireside chat with Michael S. Weiss is scheduled for September 3, 2025, at 10:20 am ET [1] - A live webcast of the fireside chat will be available on the company's website [2]